Vivodyne

Vivodyne develops a platform that creates predictive human data using lab-grown human organ models. This data accelerates the discovery of new therapeutic targets and optimizes drug development processes before clinical trials.

Vivodyne addresses the high failure rate of clinical trials, which is approximately 95%. By providing preclinical human data, the company enhances the certainty of drug efficacy and safety before entering clinical trials.

The specific location of Vivodyne's headquarters is not provided in the available content.

Vivodyne offers significant benefits, including a reduction in the reliance on animal testing, increased accuracy in predicting clinical outcomes, and a 10x acceleration in the drug development cycle compared to traditional methods.

Vivodyne was created to address the critical challenge of translating findings from animal studies to human clinical trials, ultimately aiming to improve the success rates of new therapeutics.